Literature DB >> 33764520

LmjF.36.3850, a novel hypothetical Leishmania major protein, contributes to the infection.

Shubhranshu Zutshi1, Aditya Yashwant Sarode1, Soumya Kanti Ghosh2, Mukesh Kumar Jha1, Raki Sudan1, Sunil Kumar1, Late Parag Sadhale3, Somenath Roy4, Bhaskar Saha1,5.   

Abstract

Leishmania is a protozoan parasite that resides in mammalian macrophages and inflicts the disease known as leishmaniasis. Although prevalent in 88 countries, an anti-leishmanial vaccine remains elusive. While comparing the virulent and avirulent L. major transcriptomes by microarray, PCR and functional analyses for identifying a novel virulence-associated gene, we identified LmjF.36.3850, a hypothetical protein significantly less expressed in the avirulent parasite and without any known function. Motif search revealed that LmjF.36.3850 protein shared phosphorylation sites and other structural features with sucrose non-fermenting protein (Snf7) that shuttles virulence factors. LmjF.36.3850 was predicted to bind diacylglycerol (DAG) with energy value similar to PKCα and PKCβ, to which DAG is a cofactor. Indeed, 1-oleoyl-2-acetyl-sn-glycerol (OAG), a DAG analogue, enhanced the phosphorylation of PKCα and PKCβI. We cloned LmjF.36.3850 gene in a mammalian expression vector and primed susceptible BALB/c mice followed by challenge infection. We observed a higher parasite load, comparable antibody response and higher anti-inflammatory cytokines such as IL-4 and IL-10, while expression of major anti-leishmanial cytokine, IFN-γ, remained unchanged in LmjF.36.3850-vaccinated mice. CSA restimulated LN cells from vaccinated mice after challenge infection secreted comparable IL-4 and IL-10 but reduced IFN-γ, as compared to controls. These observations suggest a skewed Th2 response, diminished IFN-γ secreting Th1-TEM cells and increased central and effector memory subtype of Th2, Th17 and Treg cells in the vaccinated mice. These data indicate that LmjF.36.3850 is a plausible virulence factor that enhances disease-promoting response, possibly by interfering with PKC activation and by eliciting disease-promoting T cells.
© 2021 John Wiley & Sons Ltd.

Entities:  

Keywords:  DNA vaccine; Leishmania; LmjF.36.3850; immunization; virulence

Mesh:

Substances:

Year:  2021        PMID: 33764520      PMCID: PMC8274150          DOI: 10.1111/imm.13331

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.215


  53 in total

1.  Immunotherapy with OX40L-Fc or anti-CTLA-4 enhances local tissue responses and killing of Leishmania donovani.

Authors:  Soombul Zubairi; Stephanie L Sanos; Sue Hill; Paul M Kaye
Journal:  Eur J Immunol       Date:  2004-05       Impact factor: 5.532

2.  CTLA4 (CD152) modulates the Th subset response and alters the course of experimental Leishmania major infection.

Authors:  B Saha; S Chattopadhyay; R Germond; D M Harlan; P J Perrin
Journal:  Eur J Immunol       Date:  1998-12       Impact factor: 5.532

Review 3.  Vaccine candidates for leishmaniasis: a review.

Authors:  Rajeev Nagill; Sukhbir Kaur
Journal:  Int Immunopharmacol       Date:  2011-05-25       Impact factor: 4.932

Review 4.  Leishmaniasis vaccine candidates for development: a global overview.

Authors:  Ali Khamesipour; Sima Rafati; Noushin Davoudi; Fereidoun Maboudi; Farrokh Modabber
Journal:  Indian J Med Res       Date:  2006-03       Impact factor: 2.375

Review 5.  Second-generation vaccines against leishmaniasis.

Authors:  Rhea N Coler; Steven G Reed
Journal:  Trends Parasitol       Date:  2005-05

6.  Toll-like receptors and CD40 modulate each other's expression affecting Leishmania major infection.

Authors:  H S Chandel; S P Pandey; D Shukla; K Lalsare; S K Selvaraj; M K Jha; B Saha
Journal:  Clin Exp Immunol       Date:  2014-05       Impact factor: 4.330

7.  Leishmania major MAP kinase 10 is protective against experimental L. major infection.

Authors:  Sangeeta Kumari; Sushma Singh; Bhaskar Saha; Piyush Kumar Paliwal
Journal:  Vaccine       Date:  2011-04-27       Impact factor: 3.641

8.  Interferon gamma in leishmaniasis.

Authors:  Peter E Kima; Lynn Soong
Journal:  Front Immunol       Date:  2013-06-19       Impact factor: 7.561

Review 9.  An overview on Leishmania vaccines: A narrative review article.

Authors:  Hossein Rezvan; Mohammad Moafi
Journal:  Vet Res Forum       Date:  2015-03-15       Impact factor: 1.054

10.  CD40 signaling is impaired in L. major-infected macrophages and is rescued by a p38MAPK activator establishing a host-protective memory T cell response.

Authors:  Amit Awasthi; Ramkumar Mathur; Aslam Khan; Bimba N Joshi; Nitya Jain; Sangeeta Sawant; Ramanamurthy Boppana; Debashis Mitra; Bhaskar Saha
Journal:  J Exp Med       Date:  2003-04-14       Impact factor: 14.307

View more
  1 in total

1.  Screening Novel Vaccine Candidates for Leishmania Donovani by Combining Differential Proteomics and Immunoinformatics Analysis.

Authors:  Jianhui Zhang; Jiao Li; Kaifeng Hu; Qi Zhou; Xiaoxiao Chen; Jinlei He; Shuangshuang Yin; Yangjian Chi; Xuechun Liao; Yuying Xiao; Hanxiao Qin; Zhiwan Zheng; Jianping Chen
Journal:  Front Immunol       Date:  2022-06-23       Impact factor: 8.786

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.